Vizrt shows how live video can be produced anywhere, without complex studio setups
Updated
April 20, 2026 1:40 PM
A camera filming a still life on a table. PHOTO: UNSPLASH
Vizrt, a media technology company, has introduced a new AI-powered tool to simplify the creation of virtual scenes in live production. Its latest release, the AI Keyer, is built around a simple idea: remove the need for green screens and make virtual production possible in almost any environment.
Traditionally, creating virtual backgrounds or augmented reality (AR) scenes requires controlled studio setups, green screens, precise lighting and skilled operators. That makes high-end visual production expensive and difficult to scale, especially for smaller teams or live, on-the-ground reporting.
The AI Keyer is designed to address that gap. It uses AI trained on real-world footage to identify people in a frame and separate them from the background in real time. This allows production teams to replace backgrounds, insert AR graphics or place presenters into virtual environments—whether they are indoors, outdoors or on location.
"Creating XR environments typically demands large infrastructure investments and requires specialized skills for daily operations. The Vizrt AI Keyer removes all these constraints, so high-quality virtual scenes and AR graphics become a reality for live productions of every size", says Edouard Griveaud, Senior Product Manager at Vizrt.
In practical terms, this means a presenter can appear in a different location without moving, a remote speaker can be placed inside a virtual event space or branded graphics can be added to live interviews without a complex setup. The system works without chroma keying, reducing both preparation time and production overhead.
This shift also reflects how the company is approaching AI more broadly. Instead of treating it as a background feature, Vizrt is positioning AI as a core part of the content creation and delivery process.
"AI is transforming the world, and the creative industries are no exception. At Vizrt, we have been on this journey for years, embedding intelligence into our solutions, empowering storytellers and delivering real, measurable impact for our customers", says Rohit Nagarajan, CEO of Vizrt. "That is not a vision for tomorrow. That is happening today. The Vizrt AI Keyer is the latest proof point of our relentless commitment to innovation. Putting breakthrough technology in the hands of every creative, at every level, everywhere in the world".
Beyond the product itself, the direction is clear. By removing the need for green screens and complex setups, tools like the AI Keyer make it easier to produce high-quality visual content in more flexible settings. The result is a production model that is less tied to physical studios and more adaptable to real-world environments, where content can be created and adjusted in real time.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.